| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- Piromidic acid
-
- $41.00
-
2026-04-22
- CAS:19562-30-2
- Purity: 98.33%
- Supply Ability: 10g
|
| | Piromidic acid Basic information |
| | Piromidic acid Chemical Properties |
| Melting point | 314-316° | | Boiling point | 430.54°C (rough estimate) | | density | 1.1895 (rough estimate) | | refractive index | 1.6000 (estimate) | | storage temp. | 0-6°C | | solubility | Chloroform (Slightly, Heated, Sonicated), Ethanol (Slightly, Heated) | | form | Solid | | pka | 4.14±0.20(Predicted) | | color | Crystals from EtOH/CHCl3 |
| Toxicity | LD50 in male, female mice, male, female rats (mg/kg): 287, 268, 177, 158 i.v.; all >4000 orally, s.c. and i.p. (Shimizu) |
| | Piromidic acid Usage And Synthesis |
| Description | Piromidic acid is a quinolone antibiotic that is active against Gram-positive and Gram-negative bacteria including S. aureus and E. coli (MICs = 10 and 1 μg/ml, respectively). It inhibits growth of nalidixic acid-sensitive strains of E. coli in an in vitro model of bacterial cystitis when used at concentrations of 10 and 50 mg/L. Piromidic acid also has antimalarial properties and is active against chloroquine-sensitive and -resistant strains of P. falciparum in vitro (IC50s = 41.4 and 14.4 μg/ml, respectively) as well as against hepatic stages of P. yoelii yoelii (IC50 = 21.6 μg/ml). | | Originator | Panacid, Dainippon, Japan ,1972 | | Uses | Antibacterial;Topoisomerase II inhibitor | | Uses | Piromidic acid is a quinolone antibacterial. | | Definition | ChEBI: Piromidic acid is a pyridopyrimidine that is 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid, substituted at position 2 by a pyrrolidin-1-yl group and at position 8 by an ethyl group. A synthetic antibacterial which is used for the treatment of urinary tract and intestinal infections. It has a role as an antibacterial drug and a DNA synthesis inhibitor. It is a quinolone antibiotic, a member of pyrrolidines, a tertiary amino compound, a monocarboxylic acid and a pyridopyrimidine. | | Manufacturing Process | 150 mg of 6-carboxy-5,8-dihydro-8-ethyl-2-methylthio-5-oxopyrido[2,3d]pyrimidine was added to 30 ml of absolute ethanol containing 1.1 g of dissolved pyrrolidine, and the mixture was reacted for 5 hours at 95°C in a sealed tube. The solvent was removed by distillation, and the residue was recrystallized from methanol-chloroform. There were obtained 111 mg of 6carboxy-5,8-dihydro-8-ethyl-5-oxo-2-pyrrolidino-pyrido[2,3-d]pyrimidine having a MP of 314° to 316°C.
The starting material is produced by reacting 6-amino-2-methylthiopyrimidine with ethoxymethylene malonic acid diethyl ester. That intermediate is thermally treated in diphenyl ether to give 6-ethoxycarbonyl-2-methylthio-5oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine. The ethoxy group is hydrolyzed off with sodium hydroxide and one nitrogen is ethylated with diethyl sulfate to give the starting material. These are the same initial steps as used in the pipemidic acid syntheses earlier in this volume. | | Therapeutic Function | Antibacterial (urinary) | | Pharmaceutical Applications | A pyrimidopyrimidine derivative with a C7-pyrrolidinyl ring, allowing a slight increase in activities against Gram-positive cocci. Its main antibacterial activity is close to that of nalidixic acid and there have been reports of renal toxicity. It is available in only a few countries. | | Safety Profile | Poison by subcutaneous and intravenous routes. Moderately toxic by skin contact and intraperitoneal routes. An antibacterial agent. When heated to decomposition it emits toxic fumes of NOx. | | References | [1] S. MINAMI J M T Shono. Pyrido [2, 3- d ] pyrimidine Antibacterial Agents. II. Piromidic Acid and Related Compounds[J]. Chemical & pharmaceutical bulletin, 1971, 45 1: 1426-1432. DOI: 10.1248/cpb.19.1426
[2] GREENWOOD D. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.[J]. Journal of Antimicrobial Chemotherapy, 1984, 13 Suppl B: 43-48. DOI: 10.1093/jac/13.suppl_b.43
[3] NASSIRA MAHMOUDI. In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp.[J]. Antimicrobial Agents and Chemotherapy, 2003, 47 8: 2636-2639. DOI: 10.1128/aac.47.8.2636-2639.2003 |
| | Piromidic acid Preparation Products And Raw materials |
|